Report from the extraordinary general meeting in SyntheticMR AB (publ)

SyntheticMR's extraordinary general meeting approved a rights issue of up to 29,777,342 shares at a subscription price of SEK 1.10 per share, raising up to SEK 32,755,076.20 and potentially increasing share capital by up to SEK 661,056.9924. Record date for preferential rights is 16 January 2026, with subscription and payment window running 20 January–3 February 2026 (board may extend); two subscription rights are required to subscribe for one new share and proceeds will be booked to the non-restricted share premium fund. The unanimous approval and clear timetable materially affect dilution and liquidity for existing shareholders and will be the primary driver of near-term stock action.

Analysis

MARKET STRUCTURE: The rights issue (max 29,777,342 new shares, SEK1.10 each, proceeds SEK32.76m) implies a maximum ~33% increase in shares outstanding (new/(old+new) ≈ 29.78/(59.55+29.78)). Direct winners are holders who can and will subscribe (or buy rights) — they avoid dilution and can increase stakes cheaply; losers are non-participating holders who face ~33% mechanical dilution and likely near-term negative price pressure. Liquidity-starved small-cap trading may magnify the share-price decline on the ex-rights date (record date 16 Jan; subscription 20 Jan–3 Feb).

RISK ASSESSMENT: Tail risks include a failed placement (raise <50% of target) forcing deeper dilution or emergency financing, partnership collapses that make proceeds insufficient, or regulatory/privacy setbacks for imaging/data businesses — any would likely trigger >50% downside. Immediate window (next 2–4 weeks): mechanical re-pricing and volatility spikes; short-term (1–3 months): cash deployment effectiveness revealed; long-term (>3 quarters): outcome depends on how proceeds are used (R&D/commercialization) and whether major shareholders backstop. Hidden dependency: insider/major-holder take-up rate — if they don’t, float and free-float concentration will shift materially.

TRADE IMPLICATIONS: If you hold or plan to hold equity, the cheapest defensive move is to participate pro rata to avoid dilution; otherwise, hedge with 30–90 day puts or buy-to-cover on weakness. Directional trade: small-cap, illiquid downside likely — consider a tactically sized short or buy-put spread ahead of the ex-rights date; cross-asset impact is minimal (no listed debt), but implied equity vol should rise — sell covered calls only after subscription.

CONTRARIAN ANGLES: Consensus will treat this as negative dilution; under-appreciated is that SEK32.8m can materially extend runway for a sub-scale medtech/systems company — if management can convert funds into a commercial partnership within 6–12 months the stock could re-rate >2x from post-issue troughs. Overdone reaction scenario: market drops 30–40% even if insiders commit to full take-up — that creates a mean-reversion trade for event-driven buyers who can finance subscription costs cheaply.

Key Decisions for Investors

• If you currently own SyntheticMR AB (publ), subscribe pro rata to the rights issue (record date 16 Jan 2026; subscription 20 Jan–3 Feb 2026) to avoid ~33% dilution — allocate cash equal to 1.10 SEK per new share entitlement (max raise SEK32.76m).
• If you do not want to fund, reduce position size to ≤0.5% NAV before the ex-rights date and purchase 30–60 day at-the-money put protection (buy puts or put spreads with strikes near current spot) sized to cover the reduced position; target cost threshold ≤5–8% of position value.
• Event-driven alternative: buy rights (or underlying if rights trade) only if market-implied price < SEK1.30 post-ex-rights (i.e., >15% upside to exercise price net costs); size position 1–2% NAV and plan to exercise by 3 Feb or sell rights prior to expiry.
• Relative value: long iShares U.S. Medical Devices ETF (IHI) 1–3% NAV and short SyntheticMR 0.5–1% NAV to rotate out of idiosyncratic small-cap medtech risk into diversified larger-cap device exposure over the next 3–6 months.